Supplementary Tables 1 - 8 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia Via Modulation of P53, PI3K/AKT, and NF-κB

PDF file - 277K, S1: Fractional Product of Webb calculations for concomitant VPA/BTZ treatment in Nalm6; S2: Ic25 and Ic50 values for HDACis; S3: Fractional Product of Webb calculations for concomitant VPA/BTZ treatment in 697, SD-1 and SEM cells and S4: for sequential combinations; S5: NF-kappaB subunits gene expression analyses in primary LC in correlation with the clinical characteristics of the BCP-ALL relapse patient cohort; S6: Mortality in the s.c.- and i.v.- xenograft mouse models; S7: Microarray analysis of the upregulated genes in Reh cells after VPA/BTZ treatment and S8: of the downregulated genes.